Promising novel therapies for the treatment of endometrial cancer

被引:33
作者
Gehrig, Paola A. [1 ]
Bae-Jump, Victoria L. [1 ]
机构
[1] Univ N Carolina, Dept Obstet & Gynecol, Div Gynecol Oncol, Chapel Hill, NC 27599 USA
关键词
Endometrial cancer; Biologic therapy; Chemotherapy; Novel therapeutics; Molecular targets; PHASE-III TRIAL; DOXORUBICIN PLUS CISPLATIN; ENDOTHELIAL GROWTH-FACTOR; PAPILLARY SEROUS CARCINOMA; HUMAN MONOCLONAL-ANTIBODY; GENE-EXPRESSION PROFILES; MICROSATELLITE INSTABILITY; FACTOR RECEPTOR; HER-2/NEU OVEREXPRESSION; PROGNOSTIC INDICATORS;
D O I
10.1016/j.ygyno.2009.10.041
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. To discuss the novel agents which are being developed for the treatment of advanced and recurrent endometrial carcinoma and to review other molecular targets that may be interesting in the treatment of this disease. While the majority of women with endometrial cancer enjoy a relatively good prognosis, the options for those women who Suffer from a disease recurrence are limited and there is a need to identify novel agents. Methods. A review of clinical trials of novel therapeutic agents and then molecular targets is provided. In addition, a review of the current literature on other potential molecular targets for endometrial cancer was performed. Results. Several phase II trials of novel agents, both alone and in combination with traditional cytotoxic chemotherapy, have been completed or are nearing completion. It appears that the targeted agents may have the most efficacy in combination with cytotoxic chemotherapy or in a multi-targeted agent approach. Conclusions. Chemotherapy offers the opportunity for a meaningful response rate in women with endometrial cancer, but the responses are often short lived and cure is uncommon in the setting of recurrent disease. The recent increase in molecular targets has led to the availability of many novel therapies. Determining how these agents are to be used, alone or in combination with "standard" therapies, needs to be defined and translational Studies are needed to develop rational combinations of these novel agents before we can move into clinical trials. (C) 2009 Elsevier Inc. All rights reserved
引用
收藏
页码:187 / 194
页数:8
相关论文
共 100 条
[1]   Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling [J].
Abraham, RT .
CURRENT OPINION IN IMMUNOLOGY, 1998, 10 (03) :330-336
[2]  
Aghajanian C, 2009, J CLIN ONCOL, V27
[3]   Consequences of the loss of p53, RB1, and PTEN: Relationship to gefitinib resistance in endometrial cancer [J].
Albitar, Lina ;
Carter, Mark B. ;
Davies, Suzy ;
Leslie, Kimberly K. .
GYNECOLOGIC ONCOLOGY, 2007, 106 (01) :94-104
[4]  
[Anonymous], 2006, J CLIN ONCOL
[5]   Synergistic Effect of Rapamycin and Cisplatin in Endometrial Cancer Cells [J].
Bae-Jump, Victoria L. ;
Zhou, Chunxiao ;
Boggess, John F. ;
Gehrig, Paola A. .
CANCER, 2009, 115 (17) :3887-3896
[6]  
Basil JB, 2000, CANCER-AM CANCER SOC, V89, P1758, DOI 10.1002/1097-0142(20001015)89:8<1758::AID-CNCR16>3.0.CO
[7]  
2-A
[8]   AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells [J].
Beltran, Pedro J. ;
Mitchell, Petia ;
Chung, Young-A ;
Cajulis, Elaina ;
Lu, John ;
Belmontes, Brian ;
Ho, Joanne ;
Tsai, Mei Mei ;
Zhu, Min ;
Vonderfecht, Steven ;
Baserga, Renato ;
Kendall, Richard ;
Radinsky, Robert ;
Calzone, Frank J. .
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (05) :1095-1105
[9]   Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits [J].
Bhaskar, Vinay ;
Fox, Melvin ;
Breinberg, Danna ;
Wong, Melanie H-L ;
Wales, Pauline E. ;
Rhodes, Susan ;
DuBridge, Robert B. ;
Ramakrishnan, Vanitha .
INVESTIGATIONAL NEW DRUGS, 2008, 26 (01) :7-12
[10]   The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer [J].
Bilbao, Cristina ;
Rodriguez, German ;
Ramirez, Raquel ;
Falcon, Orlando ;
Leon, Laureano ;
Chirino, Ricardo ;
Rivero, Juan F. ;
Falcon, Orlando, Jr. ;
Diaz-Chico, B. Nicolas ;
Diaz-Chico, Juan C. ;
Perucho, Manuel .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (03) :563-570